As India is fighting the insurmountable odds against the second wave of Wuhan virus pandemic, the first batch of 2-deoxy-D-glucose (2-DG) drug is set to be launched next week, reports Livemint.
The drug has been developed by the Defence Research Development Organisation (DRDO) lab, Institute of Nuclear Medicine and Allied Sciences, in collaboration with Hyderabad based pharmaceutical major Dr Reddy’s Laboratories. The drug can be used to treat moderate and severe cases of Wuhan virus.
The DRDO is known for developing state of the art weapons platforms for the Indian military, however, this time the scientists of DRDO have developed the 2-DG drug and it has been cleared by the Drug Controller General of India (DCGI) for emergency use in the treatment of Covid-19 patients earlier last week.
The first batch will comprise 10,000 doses of 2-DG and will be administered to patients as an adjunct therapy or an alternative treatment to assist the primary treatment.
DRDO in a statement had earlier said that during the clinical trial, the drug helped in faster recovery of hospitalized patients and reduces supplemental oxygen dependence.
During the 2-DG trials, the drug showed faster symptomatic cure than Standard of Care (SoC) for patients on various endpoints in the efficacy trends.
Click here to subscribe to The Commune on Telegram and get the best stories of the day delivered to you personally.